HCA logo

HCA Healthcare, Inc. Stock Price

NYSE:HCA Community·US$82.2b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 79 Fair Values set on narratives written by author

HCA Share Price Performance

US$373.09
22.12 (6.30%)
US$490.29
Fair Value
US$373.09
22.12 (6.30%)
23.9% undervalued intrinsic discount
US$490.29
Fair Value
Price US$373.09
AnalystConsensusTarget US$490.29
yiannisz US$629.14
AnalystLowTarget US$396.00

HCA Community Narratives

·
Fair Value US$490.29 23.9% undervalued intrinsic discount

Supplemental Payments And Policy Risks Will Shape Future Performance And Value

0users have liked this narrative
0users have commented on this narrative
31users have followed this narrative
Fair Value
·
Fair Value US$629.14 40.7% undervalued intrinsic discount

HCA Healthcare: Stability, Scale, and the Human Side of Healthcare Investing

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$396 5.8% undervalued intrinsic discount

Digital And AI Cost Pressures Will Shape A Cautious Yet Resilient Hospital Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$629.14
40.7% undervalued intrinsic discount
Fair Value
Revenue
5.03% p.a.
Profit Margin
8.53%
Future PE
17.24x
Price in 2031
US$880.59
US$490.29
23.9% undervalued intrinsic discount
Revenue
4.91% p.a.
Profit Margin
8.55%
Future PE
15.25x
Price in 2029
US$608.56
US$627.69
40.6% undervalued intrinsic discount
Revenue
5.88% p.a.
Profit Margin
8.66%
Future PE
18.79x
Price in 2029
US$780.35

Trending Discussion

No trending discussion available.

Updated Narratives

HCA logo

HCA Healthcare: Stability, Scale, and the Human Side of Healthcare Investing

Fair Value: US$629.14 40.7% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
HCA logo

HCA: Medicaid And State Directed Payments Will Reset Earnings While Undervaluation Persists

Fair Value: US$490.29 23.9% undervalued intrinsic discount
31 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
HCA logo

Digital And AI Cost Pressures Will Shape A Cautious Yet Resilient Hospital Outlook

Fair Value: US$396 5.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with solid track record.

2 Risks
4 Rewards

HCA Healthcare, Inc. Key Details

US$76.4b

Revenue

US$44.6b

Cost of Revenue

US$31.8b

Gross Profit

US$25.0b

Other Expenses

US$6.8b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 24, 2026
30.63
41.61%
8.89%
-1,612.6%
View Full Analysis

About HCA

Founded
1968
Employees
275000
CEO
Samuel Hazen
WebsiteView website
www.hcahealthcare.com

HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Recent HCA News & Updates

Seeking Alpha Jul 15

HCA Healthcare's Warning Prices In All The Bad News (Upgrade)

Summary HCA Healthcare is upgraded to "Buy" after recent underperformance, with shares now reflecting payer mix and policy headwinds. HCA's Q2 results beat expectations due to a $400 million one-time Medicaid payment, masking underlying margin compression from a worsening payer mix. Guidance was cut, with 2026 EPS now seen at $29–$30 (excluding windfall: ~$28), and free cash flow run-rate at ~$6 billion, reflecting persistent policy pressures. At 13x earnings and a 7.5% free cash flow yield, HCA appears de-risked, with fair value estimated at $400 as policy headwinds are now priced in. Read the full article on Seeking Alpha

Recent updates

No updates